Guggenheim Maintains Buy on Pfizer, Raises Price Target to $36

Benzinga Newsdesk www.benzinga.com Positive 75.8%

Neg 0% Neu 0% Pos 75.8%

Guggenheim analyst Vamil Divan maintains Pfizer (NYSE:PFE) with a Buy and raises the price target from $35 to $36.

Comments

No comments yet. Be the first!